Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ixazomib maintenance versus placebo in newly diagnosed multiple myeloma without stem cell transplantation
2014-001394-13Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib maintenance with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-001394-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001394-13.